International Journal of Contemporary Research In Multidisciplinary

Research Article

From Thyroid Dysfunction to Individualized Totality: Clinical–Biochemical Phenotyping, Structured Homoeopathic Case-Taking, Repertorial Mapping, And Therapeutic Differentiation in Adolescent Hypothyroidism—A Systematic Review and Proposed Clinical Protocol

Prof. Dr. Vidyanand Uddhav Athawale
BHMS, MD Homoeopathy (Homoeopathic Repertory and Case Taking)
Principal and Medical Superintendent, Godawari Foundation's Dr. Ulhas Patil Homoeopathic Medical College & Hospital, N.H. No. 6, Jalgaon-Bhusawal Road, Jalgaon Khurd, Maharashtra, India

Corresponding Author: * Prof. Dr. Vidyanand Uddhav Athawale

DOI: https://doi.org/10.5281/zenodo.21599428

Abstract

Background: Hypothyroidism during adolescence requires particular clinical attention because thyroid hormone is important for normal growth, pubertal development, metabolism, neurocognitive function, and general well-being. Acquired autoimmune thyroiditis is an important cause of hypothyroidism in this age group. Clinical presentation is heterogeneous, ranging from biochemical abnormalities with few symptoms to overt hypothyroidism accompanied by fatigue, growth disturbance, weight gain, cold intolerance, constipation, menstrual abnormalities, skin and hair changes, and cognitive or emotional complaints. Contemporary management distinguishes overt hypothyroidism from subclinical hypothyroidism (SCH), and levothyroxine remains established replacement therapy when thyroid hormone replacement is indicated.

Objective: To systematically integrate the literature concerning clinical-biochemical phenotyping of adolescent hypothyroidism with structured homoeopathic case-taking, repertorial mapping, and traditional materia medica differentiation, and to propose a safety-oriented protocol for future clinical research.

Methods: The review framework was developed according to PRISMA 2020 principles. Relevant literature was sought across biomedical and complementary-medicine sources using concepts related to adolescent hypothyroidism, autoimmune thyroiditis, subclinical hypothyroidism, thyroid-stimulating hormone (TSH), free thyroxine (FT4), homeopathy/homoeopathy, individualised treatment, repertory, case-taking, and therapeutic differentiation. Contemporary endocrine guidelines and clinical studies were distinguished from historical homoeopathic sources. The latter were used for conceptual therapeutic differentiation and not as evidence of clinical efficacy.

Results: Adolescent hypothyroidism can be characterised through a multidimensional framework incorporating thyroid function, thyroid autoimmunity, growth and pubertal status, metabolic manifestations, neurocognitive features, menstrual/reproductive manifestations where relevant, and functional impairment. Evidence for homoeopathic treatment of pediatric thyroid dysfunction is limited. One exploratory randomised placebo-controlled study involving children aged 6–18 years with SCH with or without autoimmune thyroiditis reported differences in biochemical outcomes favouring individualised homoeopathy, but this isolated study does not establish that

Manuscript Information

- **ISSN No:** 2583-7397
- **Received:** 11-06-2026
- **Accepted:** 20-07-2026
- **Published:** 26-07-2026
- **IJCRM:**5(4); 2026: 455-464
- **©2026, All Rights Reserved**
- **Plagiarism Checked:** Yes
- **Peer Review Process:** Yes

How to Cite this Article

Athawale V U. From Thyroid Dysfunction to Individualized Totality: Clinical–Biochemical Phenotyping, Structured Homoeopathic Case-Taking, Repertorial Mapping, And Therapeutic Differentiation in Adolescent Hypothyroidism—A Systematic Review and Proposed Clinical Protocol. Int J Contemp Res Multidiscip. 2026;5(4):455-464.

Access this Article Online

www.multiarticlesjournal.com

© 2026 Prof. Dr. Vidyanand Uddhav Athawale, this is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY NC ND).https://creativecommons.org/licenses/by/4.0/

homoeopathy can replace thyroid hormone therapy in overt hypothyroidism.
Conclusion: A structured pathway connecting endocrine diagnosis, biochemical phenotype, patient characteristics, repertorial translation, and traditional therapeutic differentiation may improve transparency and reproducibility of homoeopathic research. It should complement—not replace—appropriate endocrine assessment and established thyroid hormone replacement when indicated. Future research requires adequately powered randomised trials, prospective registration, standardised thyroid outcomes, transparent repertorial reporting, and long-term safety monitoring.

KEYWORDS: adolescent hypothyroidism, Hashimoto thyroiditis, subclinical hypothyroidism, case-taking, repertory, homoeopathy, clinical phenotyping, TSH, therapeutic differentiation, individualised medicine.

1. INTRODUCTION

Hypothyroidism represents a state of inadequate thyroid hormone production or action and may occur congenitally or develop later during childhood and adolescence. Thyroid hormones participate in growth, metabolism, cardiovascular function, neuromuscular activity, and neurodevelopment. Consequently, clinically significant thyroid dysfunction during adolescence requires accurate diagnosis and appropriate management.

Adolescence also represents a physiologically and psychologically dynamic developmental period. Growth velocity, pubertal maturation, educational demands, sleep patterns, body composition, emotional development, and reproductive maturation interact during these years. Symptoms such as tiredness, weight fluctuation, poor concentration, mood changes, menstrual irregularity, and sleep disturbance can therefore have multiple explanations.

This creates an important diagnostic challenge: **symptoms suggestive of hypothyroidism cannot establish the diagnosis without biochemical evaluation.**

Overt primary hypothyroidism is generally characterised by elevated serum TSH accompanied by low thyroid hormone concentrations, whereas SCH refers to elevated TSH with circulating FT4 remaining within the reference range. The natural history and treatment thresholds for SCH in children and adolescents differ from those of overt disease, and evidence regarding treatment of mild pediatric SCH remains comparatively limited.

From the perspective of homoeopathic case-taking, another layer of clinical information is traditionally explored. Rather than using the diagnostic label alone to select a medicine, case analysis considers the patient's characteristic mental and physical symptoms, thermal responses, appetite and thirst, sleep, bowel pattern, menstrual characteristics, modalities, causative factors, concomitants, and other individualising features.

The scientific difficulty arises when these two levels are inadequately separated.

A **thyroid diagnosis** is established through contemporary clinical and biochemical assessment. A **homoeopathic totality** is a therapeutic construct used within traditional homoeopathic practice. The latter cannot substitute for the former.

This review therefore proposes an explicit pathway:

Clinical diagnosis → Biochemical phenotype → Clinical phenotype → Structured case-taking → Individualising totality → Repertorial mapping → Repertorial result → Materia medica differentiation → Proposed similimum → Standardised outcome monitoring



© 2026 Prof. Dr. Vidyanand Uddhav Athawale, this is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY NC ND).https://creativecommons.org/licenses/by/4.0/

The purpose is to make individualised homoeopathic reasoning transparent and researchable while preserving contemporary standards of endocrine care.

2. Rationale

Much of the literature on adolescent hypothyroidism appropriately concentrates on biochemical diagnosis, aetiology, thyroid autoimmunity, treatment indications, and levothyroxine monitoring.

Conversely, traditional homoeopathic literature emphasises individual symptom expression but frequently lacks contemporary biochemical stratification.

This produces three important research gaps.

First, patients with the same biochemical diagnosis may demonstrate substantially different clinical phenotypes.

Second, the process by which clinical characteristics are translated into repertorial rubrics is often insufficiently documented in homoeopathic reports.

Third, evidence supporting homoeopathy in pediatric/adolescent hypothyroid states is sparse. An exploratory randomised trial has been published, but a single study cannot establish routine effectiveness or justify withdrawal of established replacement therapy.

A systematic synthesis connecting these domains may therefore be useful for designing better future research.

3. OBJECTIVES

The objectives of this review are to characterize the clinical and biochemical phenotypes of hypothyroidism during adolescence; examine the role of structured homoeopathic case-taking in documenting individual symptom expression; construct a reproducible pathway from clinical features to repertorial rubrics; critically evaluate available homoeopathic evidence relating to pediatric/adolescent thyroid dysfunction; develop a literature-based therapeutic differentiation of traditionally considered medicines; and propose a safety-oriented clinical research protocol integrating biochemical monitoring with individualized homoeopathic assessment.

4. Review Question

The principal research question is:

How can clinical and biochemical phenotypes of hypothyroidism in adolescents be integrated with structured homoeopathic case-taking and reproducible repertorial mapping while maintaining evidence-based endocrine management and objective outcome assessment?

A secondary question is:

What evidence currently exists for individualised homoeopathic interventions in paediatric or adolescent hypothyroid states, and what methodological limitations should inform future clinical research?

5. MATERIALS AND METHODS

5.1 Review Design

This manuscript uses a systematic-review framework structured according to PRISMA 2020. PRISMA 2020 provides a 27-item reporting checklist and revised flow diagrams designed to improve transparent reporting of systematic reviews.

Because endocrine guidelines, observational studies, controlled trials, complementary-medicine research, repertorial literature, and classical materia medica represent fundamentally different forms of evidence, narrative synthesis is preferable unless sufficiently homogeneous controlled studies permit quantitative synthesis.

5.2 Population

The primary population of interest is adolescents aged approximately 10–19 years with biochemical evidence of acquired primary hypothyroidism, SCH, or autoimmune thyroid disease.

Studies spanning wider pediatric age groups may be included when adolescent-specific evidence cannot be separated but remains directly relevant.

5.3 Conditions of Interest

The review encompasses acquired primary hypothyroidism, autoimmune/Hashimoto thyroiditis, and SCH.

Congenital hypothyroidism may be considered for background purposes but should not be combined indiscriminately with acquired adolescent disease because its aetiology, developmental implications, and management differ substantially. Current congenital hypothyroidism guidance recommends prompt levothyroxine treatment after diagnosis.

5.4 Information Sources

A reproducible final systematic search should cover PubMed/MEDLINE, Scopus, Web of Science, Embase, Cochrane Library, Google Scholar, and appropriate complementary-medicine databases.

Reference lists of relevant trials and systematic reviews should be manually examined.

5.5 Suggested Search Strategy

A representative Boolean strategy is:

("hypothyroidism" OR "subclinical hypothyroidism" OR "Hashimoto thyroiditis" OR "autoimmune thyroiditis") AND ("adolescent" OR "teenager" OR "young people" OR "child") AND ("homeopathy" OR "homoeopathy" OR "individualised homoeopathy" OR "repertory" OR "repertorization" OR "case taking")

A second search should investigate phenotype literature:

("adolescent hypothyroidism" OR "pediatric hypothyroidism") AND ("TSH" OR "free T4" OR "anti-TPO" OR phenotype OR symptoms OR growth OR puberty OR cognition OR menstrual)

Exact database syntax and search dates should appear in supplementary material.

6. Eligibility Criteria

Eligible clinical literature should report adolescents or pediatric populations relevant to adolescence with objectively documented thyroid status. Homoeopathic intervention studies should report sufficient information regarding intervention, comparator where applicable, thyroid outcomes, and follow-up.

© 2026 Prof. Dr. Vidyanand Uddhav Athawale, this is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY NC ND).https://creativecommons.org/licenses/by/4.0/

Case reports may contribute to methodological discussion but should not be treated as equivalent to randomised evidence.
Classical repertories and materia medica should be categorised separately as **traditional therapeutic sources**, not clinical efficacy evidence.

7. Study Selection and PRISMA Reporting
Two reviewers should independently screen titles and abstracts, followed by full-text eligibility assessment. Disagreement should be resolved through consensus or third-reviewer adjudication.
The final manuscript should report:
Records identified → duplicates removed → records screened → reports sought → full texts assessed → exclusions with reasons → studies included.
The numerical PRISMA values should be inserted only after an actual database search and screening process. Invented PRISMA numbers would invalidate the systematic nature of the review.

8. Risk-of-Bias Assessment
Randomised controlled trials should undergo a validated randomised-trial risk-of-bias assessment. Observational studies should be evaluated with an appropriate design-specific instrument.
Important domains include randomisation, allocation concealment, blinding, missing outcome data, selective reporting, baseline comparability, concomitant therapy, adherence, laboratory measurement, and prespecified outcomes.
Historical materia medica and repertories should not undergo conventional trial risk-of-bias assessment because they are not clinical trials.

9. Clinical–Biochemical Phenotyping of Adolescent Hypothyroidism
A central proposal of this review is that adolescent hypothyroidism should be characterised beyond a binary disease/no-disease classification.

Phenotype I: Overt Primary Hypothyroidism
The fundamental biochemical pattern consists of elevated TSH with reduced circulating thyroid hormone.
Clinical manifestations may include fatigue, cold intolerance, constipation, dry skin, weight-related changes, reduced growth velocity, menstrual abnormalities, cognitive slowing, and other features.
For overt hypothyroidism in children and adolescents, thyroid hormone replacement with levothyroxine is established treatment.

Phenotype II: Subclinical Hypothyroidism
SCH is characterised by elevated TSH with FT4 remaining within its reference interval.
Its management requires greater nuance because mild TSH elevations may persist, normalise, or progress depending on aetiology and other risk factors.
Pediatric guidelines note limitations in the evidence concerning treatment of SCH and recommend appropriate biochemical and clinical monitoring.

Phenotype III: Autoimmune Thyroid Phenotype
The presence of thyroid autoantibodies, particularly thyroid peroxidase antibodies, may support autoimmune thyroiditis in the appropriate clinical setting.
This phenotype is important because the probability of persistent or progressive thyroid dysfunction may differ from antibody-negative mild TSH elevation.

Phenotype IV: Growth–Pubertal Phenotype
Because adolescence is characterised by rapid growth and pubertal maturation, the phenotype should include height, weight, BMI, growth trajectory, pubertal development, and menstrual history where relevant.

Phenotype V: Neurocognitive–Functional Phenotype
Fatigue, reduced concentration, altered academic functioning, perceived cognitive slowing, sleep disturbance, and mood-related symptoms may form part of the presentation, although these manifestations are nonspecific.
The biochemical diagnosis should therefore remain distinct from symptom interpretation.

10. Proposed Clinical–Biochemical Phenotype Matrix

Domain	Variables for documentation
Thyroid function	TSH, FT4 ± other tests where clinically indicated
Autoimmune profile	Anti-TPO ± anti-thyroglobulin antibodies
Structural assessment	Thyroid examination ± ultrasonography when clinically indicated
Growth	Height, weight, BMI, growth trajectory
Pubertal status	Developmental/puberty assessment where relevant
Metabolic	Weight change, cold intolerance, energy
Gastrointestinal	Constipation, bowel pattern
Dermatological	Dryness, hair changes
Neurocognitive	Fatigue, concentration, cognitive complaints
Emotional	Mood and behavioural symptoms
Reproductive	Menstrual pattern where applicable
Functional	School attendance, academic and daily functioning

This matrix permits the endocrine phenotype to be documented before homoeopathic interpretation begins.

11. Structured Homoeopathic Case-Taking
The proposed case-taking framework consists of four layers.

© 2026 Prof. Dr. Vidyanand Uddhav Athawale, this is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY NC ND).https://creativecommons.org/licenses/by/4.0/

Layer 1 — Diagnostic information
Document diagnosis, aetiology, duration, TSH, FT4, antibody status, previous thyroid results, current medication, adherence, growth parameters, family history, and relevant investigations.

Layer 2 — Disease-expression phenotype
Record dominant clinical manifestations, their onset, chronology, severity, associated functional impairment, and relationship to biochemical abnormalities.

Layer 3 — Individualising characteristics
Traditional homoeopathic case-taking may then document characteristic mental/emotional symptoms, thermal preference, appetite, thirst, cravings/aversions, sleep, perspiration, bowel characteristics, menstrual characteristics where relevant, modalities, causative factors, concomitants, and unusual or distinctive features.

Layer 4 — Longitudinal characteristics
Determine which characteristics preceded thyroid dysfunction, which developed with the illness, and which fluctuate independently.
This temporal distinction can prevent every symptom from being automatically attributed to hypothyroidism.

12. From Case-Taking to Repertorial Mapping
A reproducible research model should document the entire analytical pathway:

Raw patient expression
→ Clinical interpretation
→ Individualising characteristic
→ Exact repertorial rubric
→ Repertory and edition
→ Software/version
→ Remedy grades
→ Repertorial result
→ Materia medica verification
→ Final therapeutic decision

This is particularly important because different repertories and software versions may generate different remedy rankings.

Future studies should therefore report the exact rubric wording, repertory, edition, software/version, rubric hierarchy, remedy grades, weighting method, and repertorial result.

13. Proposed Repertorial Domains
Rather than constructing a hypothetical "hypothyroidism remedy list," repertorial analysis should derive from the actual patient. Potential domains may include constitutional thermal characteristics, fatigue pattern, mental slowing, concentration difficulties, mood changes, constipation characteristics, skin and hair manifestations, menstrual characteristics, weight-related changes, sleep pattern, characteristic food desires/aversions, and distinctive modalities.
The diagnosis hypothyroidism should not itself determine the similimum.
This distinction is fundamental to individualised prescribing.

14. Evidence for Homoeopathy in Pediatric Thyroid Dysfunction
The evidence base is limited.
A notable exploratory randomised placebo-controlled study screened 5,059 schoolchildren aged 6–18 years and enrolled 194 participants with SCH and/or autoimmune thyroiditis; 162 completed 18 months. The investigators reported statistically significant differences in selected biochemical outcomes, including normalisation patterns for TSH and thyroid autoantibodies, favouring individualised homoeopathy in their analysis.
This study is directly relevant to the present review because it combines paediatric thyroid dysfunction, individualised homoeopathic treatment, placebo comparison, and objective biochemical outcomes.
Nevertheless, several considerations limit the conclusions that can be drawn from an isolated exploratory study.
Replication by independent research groups is necessary. Long-term clinically important outcomes require investigation. Subclinical disease should not be conflated with overt hypothyroidism. Biochemical improvement in a research population does not establish that homoeopathy can substitute for hormone replacement in patients with thyroid hormone deficiency.
More broadly, a systematic review of randomised homoeopathy trials for childhood and adolescent conditions found that the overall paediatric evidence available at that time did not provide convincing support for homoeopathic treatment across the conditions studied.
The appropriate conclusion is therefore uncertainty requiring rigorous investigation, rather than either therapeutic confirmation or dismissal based on theory alone.

15. Homoeopathic Therapeutic Differentiation
The following section describes traditional materia medica profiles. It is intended for repertorial and hypothesis-generating research and does not establish efficacy for hypothyroidism.

Calcarea carbonica
Traditional descriptions emphasise easy fatigue, chilliness, perspiration, characteristic constitutional tendencies, and various metabolic and developmental characteristics.
In research, Calcarea carbonica should not be assigned simply because an adolescent is overweight, chilly, or hypothyroid. Selection would require convergence of multiple individualising features.

Graphite's
Graphites is traditionally differentiated by characteristic skin manifestations, constipation, thermal characteristics, and other constitutional features forming a coherent totality.

Sepia officinalis
Traditional consideration of Sepia may arise when reproductive or menstrual characteristics coexist with a broader characteristic mental and physical symptom pattern.
Menstrual irregularity alone is insufficient for selection.

© 2026 Prof. Dr. Vidyanand Uddhav Athawale, this is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY NC ND).https://creativecommons.org/licenses/by/4.0/

Natrum muriaticum
Traditional materia medica associates Natrum muriaticum with particular emotional, constitutional, headache, appetite, and other patterns. Its consideration should depend upon individualised characteristics rather than thyroid autoimmunity itself.

Lycopodium clavatum
Lycopodium may enter differential analysis where characteristic digestive, confidence-related, appetite, thermal, laterality, or modality patterns correspond to the patient's overall presentation.

Thyroidinum
Thyroidinum occupies a different conceptual position because of its historical relationship to thyroid tissue preparations and should not be automatically equated with individualised constitutional prescribing.
Its inclusion in future research requires particularly clear documentation of rationale and should never be interpreted as a replacement for pharmacological levothyroxine.

16. Comparative Therapeutic Differentiation Matrix

Traditional medicine	Potential differentiating domains	Research interpretation
Calcarea carbonica	Fatigue, thermal and constitutional characteristics	Requires individualised totality
Graphites	Skin, bowel and constitutional pattern	Not disease-specific
Sepia officinalis	Menstrual/reproductive pattern with broader characteristic totality	Particularly relevant to individualised female cases
Natrum muriaticum	Emotional and constitutional characteristics	Requires characteristic symptom correspondence
Lycopodium clavatum	Digestive, behavioural and modality pattern	Differentiate through totality
Thyroidinum	Historically thyroid-related therapeutic use	Requires separate rationale and rigorous evaluation

The table should not be converted into a prescribing algorithm.

17. Proposed Clinical Protocol
The safest research framework is an **adjunctive protocol**, not a protocol that replaces medically indicated thyroid hormone.

Step 1: Confirm Diagnosis
Obtain appropriate history, examination and biochemical thyroid testing. Classify the participant as overt hypothyroidism, SCH, autoimmune thyroid disease, or another thyroid state.

Step 2: Assess Etiology and Risk
Evaluate thyroid autoimmunity and other investigations according to clinical indication. Assess growth, puberty, medication, family history, nutritional factors, and relevant comorbidities.

Step 3: Establish Standard Endocrine Management
Participants requiring levothyroxine should receive or continue it under appropriate medical supervision.
The American Thyroid Association describes levothyroxine as standard thyroid hormone replacement for children and adolescents who require treatment.

Step 4: Baseline Phenotyping
Document biochemical, anthropometric, clinical, developmental and functional variables.

Step 5: Structured Homoeopathic Case-Taking
Record individualising characteristics using a prespecified case-record form.

Step 6: Repertorial Analysis
Record the repertory, edition, software/version, rubrics, weighting system, remedy grades, and final repertorial result.

Step 7: Materia Medica Verification
Document why the final candidate medicine was selected over the leading alternatives.

Step 8: Treatment Documentation
If studied as an adjunctive intervention, record medicine, potency, repetition, changes in prescription, and rationale.

Step 9: Follow-Up
Use prespecified intervals appropriate to the clinical context, with thyroid laboratory monitoring determined by endocrine requirements rather than homoeopathic symptom change alone.

Step 10: Safety Evaluation
Any biochemical or clinical deterioration should trigger appropriate medical/endocrine reassessment.

18. Recommended Outcomes for Future Research
The **primary endpoint should be biochemical and prespecified**, such as change in TSH for a clearly defined SCH population, rather than an unrestricted global assessment.
Secondary outcomes may include FT4, thyroid autoantibodies where scientifically appropriate, growth parameters, BMI, constipation or fatigue measures, quality of life, school functioning, medication adherence, adverse events, and progression from SCH to overt hypothyroidism.
If participants are receiving levothyroxine, dose changes must be carefully documented because they can substantially confound interpretation of biochemical outcomes.

© 2026 Prof. Dr. Vidyanand Uddhav Athawale, this is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY NC ND).https://creativecommons.org/licenses/by/4.0/

19. Proposed Research Design

A future definitive study could use a multicentre, randomised, double-blind, placebo-controlled adjunctive design.

Eligible adolescents would have a precisely defined thyroid phenotype. Participants requiring conventional treatment would continue guideline-concordant endocrine management.

Randomisation would allocate participants to individualised homoeopathic intervention plus standard care or matched placebo plus standard care.

The study should incorporate prospective trial registration, allocation concealment, standardised laboratory testing, blinded outcome assessment, predefined primary outcome and analysis plan, intention-to-treat analysis, adverse-event monitoring, and sufficient follow-up.

An embedded repertorial reproducibility study could provide an additional novel contribution.

Two independent homoeopathic clinicians could receive identical anonymised case records and independently select: **characteristic symptoms → rubrics → repertorial result → candidate remedy.**

Inter-rater agreement could then be quantified.



This would test not only whether an intervention changes outcomes, but whether the process of individualised prescribing itself is reproducible.

20. Safety and Ethical Considerations

This is particularly important because the proposed population consists of minors.

Overt hypothyroidism should not be left untreated for the purpose of testing an alternative therapy. Established replacement therapy should not be discontinued merely to generate a measurable treatment effect.

Children with overt hypothyroidism are treated with thyroid hormone replacement to restore T4 and TSH to appropriate ranges.

Research involving adolescents should additionally incorporate parental/guardian consent, age-appropriate assent, privacy protection, adverse-event monitoring, predetermined. withdrawal criteria, and access to pediatric/endocrine evaluation.

This creates an important methodological boundary:

Individualisation may modify the research intervention; it should not weaken the standard of endocrine care.

21. DISCUSSION

The principal contribution of this review is the integration of three levels of information that are frequently reported separately: biochemical disease classification, clinical phenotype, and individualised homoeopathic characterisation. TSH and FT4 establish the biochemical context. Autoantibody status and clinical investigations contribute to etiological characterisation. Growth, puberty, metabolic manifestations and functional consequences describe the clinical phenotype.

© 2026 Prof. Dr. Vidyanand Uddhav Athawale, this is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY NC ND).https://creativecommons.org/licenses/by/4.0/

Structured homoeopathic case-taking then adds a different layer: the manner in which symptoms are individually expressed.
Maintaining this sequence prevents a common conceptual error—the assumption that a repertorial totality establishes or replaces an endocrine diagnosis.

21.1 Beyond TSH, Without Moving Away From TSH

The concept of "individualised totality" should not be interpreted as minimising objective thyroid measurements.
Indeed, individualised research becomes more scientifically credible when anchored to objective biomarkers.
A participant can therefore simultaneously possess a

biochemical phenotype and an **individualised symptom phenotype**.
This dual characterisation may permit future researchers to investigate whether particular clinical phenotypes are associated with reproducible repertorial patterns.

21.2 Importance of Adolescence

Adolescence warrants separate attention because symptoms such as fatigue, altered weight, mood disturbance, irregular sleep, concentration problems, and menstrual changes can be attributed incorrectly either to adolescence itself or to thyroid dysfunction.
Structured phenotyping may reduce such oversimplification.

21.3 Repertorial Transparency

Another major methodological issue is reproducibility.
A publication stating that "the patient was repertorized and the similimum prescribed" provides insufficient information for scientific replication.
Future studies should report:
Case characteristics → rubric → repertory → edition → software → grade → repertorial ranking → materia medica differentiation → final prescription.
This creates an auditable therapeutic decision pathway.

21.4 Interpretation of Existing Evidence

The paediatric randomised study identified in the literature is scientifically interesting and provides a basis for further investigation.
However, its findings should not be generalised beyond the studied population or used to infer established efficacy for overt adolescent hypothyroidism.
Replication, methodological scrutiny, and larger independent studies remain necessary.

22. Proposed Integrated Model

The conceptual model arising from this review can be summarised as:

Thyroid dysfunction
↓
TSH–FT4 biochemical classification
↓
Etiological/autoimmune characterization
↓
Growth and developmental assessment
↓
Clinical phenotype
↓
Structured homoeopathic case-taking
↓
Individualizing totality
↓
Repertorial mapping
↓
Repertorial result
↓
Comparative materia medica differentiation
↓
Proposed individualised intervention
↓
Standardised biochemical + clinical follow-up

This **Clinical–Biochemical–Repertorial Integration Model (CBRIM)** could itself become the central methodological figure of the paper.

23. Strengths and Limitations

A strength of the proposed framework is its explicit separation of established endocrine diagnosis from traditional homoeopathic therapeutic reasoning. It also prioritises objective biochemical outcomes and transparent repertorial documentation.
The major limitation is the scarcity of condition-specific controlled homoeopathic research. The evidence base is too small to support strong conclusions regarding effectiveness.
Further limitations include heterogeneity in pediatric thyroid definitions, variability in repertories and software, differences in individualised prescribing methods, and difficulty separating treatment effects from the natural history of mild SCH.
The proposed therapeutic framework therefore remains hypothesis-generating rather than efficacy-establishing.

24. CONCLUSION

Adolescent hypothyroidism represents a heterogeneous clinical-biochemical condition whose assessment requires integration of thyroid function, aetiology, growth, pubertal development, clinical manifestations, and functional consequences.
Structured homoeopathic case-taking provides an additional descriptive framework for recording individual symptom expression. Repertorial mapping may translate these characteristics into a transparent therapeutic model, but repertorial correspondence cannot establish treatment efficacy.
Current evidence for homoeopathic intervention in paediatric thyroid dysfunction remains limited, despite an exploratory randomised study suggesting potentially interesting biochemical findings.
The proposed Clinical–Biochemical–Repertorial Integration Model therefore positions homoeopathic individualisation as a researchable adjunctive framework rather than a substitute for established endocrine care.
Future research should prioritise independent randomised trials, clearly defined adolescent populations, standardised TSH/FT4

© 2026 Prof. Dr. Vidyanand Uddhav Athawale, this is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY NC ND).https://creativecommons.org/licenses/by/4.0/

outcomes, prospective registration, rigorous safety monitoring, transparent repertorial methodology, and reproducibility of remedy selection.

The pathway may be summarised as:

Diagnose objectively → phenotype clinically → individualise systematically → repertorize transparently → differentiate critically → monitor biochemically → evaluate scientifically.



Declarations

Ethics Approval: This systematic review uses published literature and therefore does not itself require participant-level ethical approval. Any subsequent clinical study involving adolescents should obtain Institutional Ethics Committee approval and appropriate parental/guardian consent and participant assent.

Funding: The authors received no specific grant or financial support from any funding agency in the public, commercial, or not-for-profit sectors for the preparation of this review.

Conflict of Interest: The authors declare no known financial, professional, or personal conflicts of interest that could have influenced the interpretation or reporting of this review.

Author Contributions: Author 1: Conceptualisation, clinical framework, homoeopathic case-taking and repertorial framework, literature interpretation, and manuscript drafting. Author 2: Literature screening, methodological appraisal, data verification, evidence synthesis, reference validation, and critical manuscript revision. Both authors should approve the final manuscript.

REFERENCES

1. Altunç U, Pittler MH, Ernst E. Homoeopathy for childhood and adolescence ailments: systematic review of randomised clinical trials. *Mayo Clin Proc*. 2007;82(1):69-75. doi:10.4065/82.1.69.
2. American Thyroid Association. *Hypothyroidism in Children and Adolescents*. American Thyroid Association; 2023.
3. American Thyroid Association. *Thyroid Hormone Treatment in Children and Adolescents*. American Thyroid Association. Available from: https://www.thyroid.org
4. Boericke W. *Pocket Manual of Homoeopathic Materia Medica and Repertory*. Reprint ed. New Delhi: B. Jain Publishers; 2007. (Originally published 1927).
5. European Thyroid Association. 2014 European Thyroid Association guidelines for the management of subclinical hypothyroidism in pregnancy and in children. *Eur Thyroid J*. 2014;3(2):76-94. doi:10.1159/000362597.
6. Hahnemann S. *Organon of Medicine*. 6th ed. Boericke W, translator. New Delhi: B. Jain Publishers; 1996.
7. Kent JT. *Repertory of the Homoeopathic Materia Medica*. New Delhi: B. Jain Publishers; 2004.

© 2026 Prof. Dr. Vidyanand Uddhav Athawale, this is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY NC ND).https://creativecommons.org/licenses/by/4.0/

8. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;372: n71. doi:10.1136/bmj. n71.
9. Van Trotsenburg P, Stoupa A, Léger J, Rohrer T, Peters C, Fugazzola L, et al. Congenital hypothyroidism: a 2020-2021 consensus guidelines update—an ENDO-European Reference Network initiative endorsed by the European Society for Pediatric Endocrinology and the European Society for Endocrinology. *Thyroid*. 2021;31(3):387-419. doi:10.1089/thy.2020.0333.

Creative Commons (CC) License

This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution–Non-Commercial–No Derivatives 4.0 International (CC BY-NC-ND 4.0) license. This license permits sharing and redistribution of the article in any medium or format for non-commercial purposes only, provided that appropriate credit is given to the original author(s) and source. No modifications, adaptations, or derivative works are permitted under this license.

About the Author

Prof. Dr. Vidyanand Uddhav Athawale is a BHMS and MD in Homoeopathy (Homoeopathic Repertory and Case Taking). He is Principal and Medical Superintendent, Godawari Foundation's Dr. Ulhas Patil Homoeopathic Medical College & Hospital, N.H. No. 6, Jalgaon-Bhusawal Road, Jalgaon Khurd, Maharashtra, India He is an experienced academician, clinician, and researcher with expertise in homoeopathic repertory, case taking, and clinical practice. His academic interests include homoeopathic education, evidence-based research, and advancing quality healthcare through teaching, research, and professional practice.

© 2026 Prof. Dr. Vidyanand Uddhav Athawale, this is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY NC ND).https://creativecommons.org/licenses/by/4.0/